<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pmed</journal-id><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0020376</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correction</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Infectious Diseases</subject>
          <subject>Microbiology</subject>
          <subject>Biochemistry/Drug Discovery</subject>
          <subject>Public Health and Epidemiology</subject>
          <subject>Non-Clinical Medicine/Health Policy</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>Infectious Diseases</subject>
          <subject>Medicine in Developing Countries</subject>
          <subject>Drugs and adverse drug reactions</subject>
          <subject>Public Health</subject>
          <subject>International health</subject>
          <subject>Health Policy</subject>
          <subject>Microbiology</subject>
        </subj-group>
      </article-categories><title-group><article-title>Correction: A Breakthrough in R&amp;D for Neglected Diseases: New Ways to Get the Drugs We Need</article-title><alt-title alt-title-type="running-head">Correction</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Moran</surname>
            <given-names>Mary</given-names>
          </name>
        </contrib>
      </contrib-group><pub-date pub-type="ppub">
        <month>10</month>
        <year>2005</year>
      </pub-date><pub-date pub-type="epub">
        <day>25</day>
        <month>10</month>
        <year>2005</year>
      </pub-date><volume>2</volume><issue>10</issue><elocation-id>e376</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2005</copyright-year><copyright-holder>Public Library of Science</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article page="e302" related-article-type="corrected-article" vol="2" xlink:href="info:doi/10.1371/journal.pmed.0020302" xlink:title="Neglected Diseases" xlink:type="simple">
				<article-title>A Breakthrough in R&amp;D for Neglected Diseases: New Ways to Get the Drugs We Need</article-title>
			</related-article></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title/>
      <p>In <italic>PLoS Medicine</italic>, volume 2, issue 9, DOI: <ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0020302" xlink:type="simple">10.1371/journal.pmed.0020302</ext-link></p>
      <p>In the third paragraph of the section “Neglected-Disease R&amp;D Activity,” the sentence “Nearly one-third of these projects are at the clinical trial stage, including seven drugs now in Phase III trials…” should read instead “Nearly one-third of these projects are at the clinical trial stage, including six drugs now in Phase III trials….”</p>
    </sec>
  </body>
</article>